脑肿瘤干细胞标志物的研究进展

doi:10.3760/cma.j.issn.1673-422X.2014.12.007

摘要/Abstract

摘要： 脑肿瘤干细胞(BTSC) 在肿瘤发生和发展过程中起着关键作用。在脑肿瘤肿瘤干细胞表面存在一群特殊的标志物，可以对干细胞、前体细胞和肿瘤干细胞进行分选。近年来研究比较多的肿瘤标志物有CD133、神经巢蛋白、高迁移率族蛋白组A1、A2B5等，对这些标志物的不断深入研究中取得了一定突破。

关键词: 肿瘤干细胞, 神经胶质瘤

Abstract: Brain tumor stem cells(BTSCs) play a key role in tumorigenesis and tumor development.There are a group of special markers in the surface of brain tumor stem cells, which can sorts stem cells, precursor cells and cancer stem cells. In recent years, the studies of CD133, Nestin, highmobility group A1, A2B5 have made some breakthroughs.

Key words: Neoplastic stem cells, Glioma

吴斌, 夏亮. 脑肿瘤干细胞标志物的研究进展[J]. 国际肿瘤学杂志, 2014, 41(12): 899-901.

WU Bin, XIA Liang. Progression of brain tumor stem cell markers[J]. Journal of International Oncology, 2014, 41(12): 899-901.

参考文献

［1］ Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice［J］. Nature, 1994, 367(6464): 645648. ［2］ Yin AH, Miraglia S, Zanjani ED, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells［J］. Blood, 1997, 90(12): 50025012. ［3］ Shmelkov SV, Jun L, St Clair R, et al. Alternative promoters regulate transcription of the gene that encodes stem cell surface protein AC133［J］. Blood, 2004, 103(6): 20552061. ［4］ Yu Y, Flint A, Dvorin EL, et al. AC1332, a novel isoform of human AC133 stem cell antigen［J］. J Biol Chem, 2002, 277(23): 2071120716. ［5］ Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells［J］. Nature, 2004, 432(7015): 396401. ［6］ Singh S, Dirks PB. Brain tumor stem cells: identification and concepts［J］. Neurosurg Clin N Am, 2007, 18(1): 3138, viii. ［7］ He H, Li MW, Niu CS. The pathological characteristics of glioma stem cell niches［J］. J Clin Neurosci, 2012, 19(1): 121127. ［8］ Kahlert UD, Bender NO, Maciaczyk D, et al. CD133/CD15 defines distinct cell subpopulations with differential in vitro clonogenic activity and stem cellrelated gene expression profile in in vitro propagated glioblastoma multiformederived cell line with a PNETlike component［J］. Folia Neuropathol, 2012, 50(4): 357368. ［9］ Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response［J］. Nature, 2006, 444(7120): 756760. ［10］ Neuzil J, Tomasetti M, Zhao Y, et al. Vitamin E analogs, a novel group of "mitocans," as anticancer agents: the importance of being redoxsilent［J］. Mol Pharmacol, 2007, 71(5): 11851199. ［11］ Wu A, Wiesner S, Xiao J, et al. Expression of MHC I and NK ligands on human CD133+ glioma cells: possible targets of immunotherapy［J］. J Neurooncol, 2007, 83(2): 121131. ［12］ Beier D, Hau P, Proescholdt M, et al. CD133(+) and CD133() glioblastomaderived cancer stem cells show differential growth characteristics and molecular profiles［J］. Cancer Res, 2007, 67(9): 40104015. ［13］ Joo KM, Kim SY, Jin X, et al. Clinical and biological implications of CD133positive and CD133negative cells in glioblastomas［J］. Lab Invest, 2008, 88(8): 808815. ［14］ Cattaneo E, McKay R. Proliferation and differentiation of neuronal stem cells regulated by nerve growth factor［J］. Nature, 1990, 347(6295): 762765. ［15］ Tohyama T, Lee VM, Rorke LB, et al. Nestin expression in embryonic human neuroepithelium and in human neuroepithelial tumor cells［J］. Lab Invest, 1992, 66(3): 303313. ［16］ Rutka JT, Ivanchuk S, Mondal S, et al. Coexpression of nestin and vimentin intermediate filaments in invasive human astrocytoma cells［J］. Int J Dev Neurosci, 1999, 17(56): 503515. ［17］ Schiffer D, Manazza A, Tamagno I. Nestin expression in neuroepithelial tumors［J］. Neurosci Lett, 2006, 400(12): 8085. ［18］ Chang ZG, Yang LY, Wang W, et al. Determination of high mobility group A1 (HMGA1) expression in hepatocellular carcinoma: a potential prognostic marker［J］. Dig Dis Sci, 2005, 50(10): 17641770. ［19］ Manivannan P, Siddaraju N, Jatiya L, et al. Role of proangiogenic marker galectin3 in follicular neoplasms of thyroid［J］. Indian J Biochem Biophys, 2012, 49(5): 392394. ［20］ Goldammer T, Owens E, Brunner RM, et al.Assignment of syndecan 2 (SDC2)gene to cattle chromosome band 14q22 and thymus high mobility group box protein TOX (TOX)(2) gene to cattle chromosome band 14q17q18 by in situ hybridization［J］. Cytogenet Genome Res, 2002, 98(4): 311B. ［21］ Zhang Y, Ma T, Yang S, et al. Highmobility group A1 proteins enhance the expression of the oncogenic miR222 in lung cancer cells［J］. Mol Cell Biochem, 2011, 357(12): 363371. ［22］ Rho YS, Lim YC, Park IS, et al. High mobility group HMGI(Y) protein expression in head and neck squamous cell carcinoma［J］. Acta Otolaryngol, 2007, 127(1):7681. ［23］ Fan H, Guo H, Zhang IY, et al. The different HMGA1 expression of total population of glioblastoma cell line U251 and glioma stem cells isolated from U251［J］. Brain Res, 2011, 1384: 914. ［24］ Donato G, Martinez Hoyos J, Amorosi A, et al. High mobility group A1 expression correlates with the histological grade of human glial tumors［J］. Oncol Rep, 2004, 11(6): 12091213. ［25］ Ogawa S, Tokumoto Y, Miyake J, et al. Immunopanning selection of A2B5positive cells increased the differentiation efficiency of induced pluripotent stem cells into oligodendrocytes［J］. Neurosci Lett, 2011, 489(2): 7983. ［26］ Baracskay KL, Kidd GJ, Miller RH, et al. NG2positive cells generate A2B5positive oligodendrocyte precursor cells［J］. Glia, 2007, 55(10): 10011010. ［27］ Ogden AT, Waziri AE, Lochhead RA, et al. Identification of A2B5+CD133- tumorinitiating cells in adult human gliomas［J］. Neurosurgery, 2008, 62(2): 505514. ［28］ Tchoghandjian A, Baeza N, Colin C, et al. A2B5 cells from human glioblastoma have cancer stem cell properties［J］. Brain Pathol, 2010, 20(1): 211221. ［29］ Xu M, Yao Y, Hua W, et al. Mouse glioma immunotherapy mediated by A2B5+ GL261 cell lysatepulsed dendritic cells［J］. Neurooncol, 2014, 116(3): 497504.

[1]	刘萍萍, 何学芳, 张翼, 杨旭, 张珊珊, 季一飞. 原发性脑胶质瘤患者术后复发危险因素及预测模型构建[J]. 国际肿瘤学杂志, 2024, 51(4): 193-197.
[2]	肖楠, 孙鹏飞. 氧化应激在胶质瘤放化疗敏感性中的研究进展[J]. 国际肿瘤学杂志, 2022, 49(6): 357-361.
[3]	孔春禹, 孙鹏飞. SLC7A11与胶质瘤[J]. 国际肿瘤学杂志, 2022, 49(10): 604-607.
[4]	郭世豪, 任叶青, 郭庚. 脑胶质瘤血管生成拟态分子机制[J]. 国际肿瘤学杂志, 2021, 48(6): 362-365.
[5]	王宪伟, 史美燕, 王凤芹, 齐福, 王朝喆, 周飞. TSA上调miR-4298靶向抑制PADI4表达在诱导U251细胞凋亡中的作用[J]. 国际肿瘤学杂志, 2021, 48(4): 193-199.
[6]	魏永健, 胡进静, 李汛. CDCA8与肿瘤发生发展及干细胞干性维持的关系[J]. 国际肿瘤学杂志, 2021, 48(4): 216-219.
[7]	张雯, 胡伟国, 宋启斌. 3D-ASL与DCE-MRI在脑胶质瘤复发与放射性脑坏死鉴别诊断中的价值[J]. 国际肿瘤学杂志, 2021, 48(10): 631-634.
[8]	赵聪选, 于韬. 胶质瘤相关基因的挖掘及预测[J]. 国际肿瘤学杂志, 2020, 47(5): 293-296.
[9]	南阳, 钟跃. 长非编码RNA在神经胶质瘤研究中的新进展[J]. 国际肿瘤学杂志, 2020, 47(2): 98-102.
[10]	张雯, 宋启斌, 胡伟国. 多模态磁共振成像在脑胶质瘤中的临床应用[J]. 国际肿瘤学杂志, 2020, 47(11): 686-690.
[11]	陈亮, 秦军, 雷军荣, 刘俊, 王璐. miR-1254通过靶向CSF-1抑制胶质瘤细胞的增殖和侵袭能力[J]. 国际肿瘤学杂志, 2020, 47(10): 577-584.
[12]	张千慧, 张洋, 宿伟鹏, 张宋安, 刘攀, 赵化荣. LSD1、MGMT和Ki-67在高级别胶质瘤中的表达及对预后的影响[J]. 国际肿瘤学杂志, 2019, 46(9): 519-525.
[13]	衣琳, 邱实. 紫草素抗胶质瘤效应及其作用机制[J]. 国际肿瘤学杂志, 2019, 46(8): 489-491.
[14]	亢野,李建一,杨向红. 三阴性乳腺癌干细胞研究进展[J]. 国际肿瘤学杂志, 2019, 46(6): 362-365.
[15]	赵国丽1，2,刘恒铫1,张月英2 . 微小RNA在肺癌干细胞中的调控作用[J]. 国际肿瘤学杂志, 2019, 46(4): 231-234.